SynthesisNeuroradiology2025
Cangrelor, a newer P2Y12 inhibitor, in neuro-interventional procedures: a systematic review and updated meta-analysis.
Synthesis in Neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intravenous cangrelor as rescue therapy for acute thrombosis in neuroendovascular procedures: illustrative cases.Journal of neurosurgery. Case lessons · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCangrelor, a reversible P2Y12 receptor inhibitor commonly utilized in cardiovascular interventions, is increasingly being investigated for its potential in cerebrovascular applications. This study presents a comprehensive evaluation of its safety and efficacy in neuro-interventional procedures, based on a systematic review and meta-analysis of recent evidence.
methodsWe searched PubMed, Embase, Cochrane, Web of Science, and Scopus for studies on endovascular therapy with cangrelor-based intravenous antiplatelet therapy for cerebrovascular pathologies. Endpoints included 90-day functional outcomes, successful reperfusion (mTICI 2b-3), mortality, symptomatic intracranial hemorrhage (sICH), hemorrhagic transformation, gastrointestinal bleeding, intraprocedural complications (in-stent thrombosis, thromboembolic events), and retroperitoneal hematoma. Single-proportion analysis with 95% CIs under a random-effects model was conducted.
resultsSeventeen studies with 646 patients were included. Favorable 90-day functional outcomes occurred in 57.06% (44.37-69.76%), and successful recanalization in 98.74% (96.63-100.00%). Rates of hemorrhagic transformation, sICH, gastrointestinal bleeding, and retroperitoneal hematoma were 24.06%, 4.64%, 0.02%, and 0.07%, respectively. Intraprocedural in-stent thrombosis occurred in 0.28%, thromboembolic events in 0.48%, and 90-day all-cause mortality was 7.94%.
conclusionThe findings suggest that intravenous cangrelor, used as antiplatelet therapy following neuro-interventional procedures, is both safe and effective. This is reflected in high rates of favorable clinical outcomes, successful recanalization, and low complication rates.
Indexed as
Identifiers
40156771What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.